P70S6K 1 regulation of angiogenesis through VEGF and HIF-1α expression

Biochemical and Biophysical Research Communications

Volumn 398, Issue 3, 2010, Pages 395-399

  Bian, Chuan Xiu ^a   Shi, Zhumei ^a   Meng, Qiao ^b   Jiang, Yue ^b   Liu, Ling Zhi ^b   Jiang, Bing Hua ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

HIF 1; P70S6K1; SiRNA; Tumor angiogenesis; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P70 RIBOSOMAL S6 KINASE 1; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955272978     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.080     Document Type: Article

References (34)

1. Chung J., Grammer T.C., Lemon K.P., Kazlauskas A., Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994, 370:71-75.
2. Martin K.A., Blenis J. Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv. Cancer Res. 2002, 86:1-39.
3. Aoki M., Blazek E., Vogt P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 2001, 98:136-141.
4. Miyakawa M., Tsushima T., Murakami H., Wakai K., Isozaki O., Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr. J. 2003, 50:77-83.
5. Ghayad S.E., Cohen P.A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat. Anticancer Drug Discov. 2010, 5:29-57.
6. Trinh X.B., Tjalma W.A., Vermeulen P.B., Van den E.G., Van der Auwera I., Van Laere S.J., Helleman J., Berns E.M., Dirix L.Y., van Dam P.A. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer 2009, 100:971-978.
7. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J., Frost P., Dreisbach V., Blenis J., Gaciong Z., Fisher P., Sawyers C., Hedrick-Ellenson L., Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten mice. Proc. Natl. Acad. Sci. USA 2001, 98:10320-10325.
8. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98:10314-10319.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
10. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
11. Sharma R.A., Harris A.L., Dalgleish A.G., Steward W.P., O'Byrne K.J. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol. 2001, 2:726-732.
12. Granci V., Dupertuis Y.M., Pichard C. Angiogenesis as a potential target of pharmaconutrients in cancer therapy. Curr. Opin. Clin. Nutr. Metab. Care 2010, 417-422.
13. Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., Yao D., Tang Y., Chen X., Yang Z., Wang G., Li X., Zhao J., Ding H., Reed E., Li Q.Q. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004, 24:1973-1979.
14. Chen C.A., Cheng W.F., Lee C.N., Chen T.M., Kung C.C., Hsieh F.J., Hsieh C.Y. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol. Oncol. 1999, 74:235-240.
15. Ghosh S., Maity P. Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients. Pathol. Oncol. Res. 2004, 10:104-108.
16. Diniz Bizzo S.M., Meira D.D., Lima J.M., Mororo J.S., Casali-da-Rocha J.C., Ornellas M.H. Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 2010, 109:113-117.
17. Byrne A.T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J.I., Yancopoulos G.D., Jaffe R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 2003, 9:5721-5728.
18. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001, 12:363-369.
19. Trisciuoglio D., Iervolino A., Zupi G., Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol. Biol. Cell 2005, 16:4153-4162.
20. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
21. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22:7004-7014.
22. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002, 100:3767-3775.
23. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
24. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K., Testa J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
25. Frost P., Moatamed F., Hoang B., Shi Y., Gera J., Yan H., Frost P., Gibbons J., Lichtenstein A. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004, 104:4181-4187.
26. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
27. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 2000, 97:1749-1753.
28. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997, 16:3693-3704.
29. Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996, 58:373-395.
30. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
31. Eliceiri B.P., Klemke R., Stromblad S., Cheresh D.A. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 1998, 140:1255-1263.
32. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000, 60:3504-3513.
33. Burroughs K.D., Oh J., Barrett J.C., DiAugustine R.P. Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?. Mol. Cancer Res. 2003, 1:312-322.
34. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, 277:38205-38211.